Real-world Evaluation of Imipenem/cilastatin/relebactam across US Medical Centers

Ryan K. Shields,Emre Yucel,Vladimir Turzhitsky,Sanjay Merchant, Jae S. Min,Alexandre H. Watanabe

Journal of Global Antimicrobial Resistance（2024）

引用 0|浏览2

暂无评分

摘要

We assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support. The in-hospital mortality rate was 24%. These data advance our understanding of real-world indications and outcomes of imipenem/cilastatin/relebactam use.

查看译文

关键词

complicated urinary tract infections,gram-negative infection,hospital-acquired/ventilator-associated bacterial pneumonia,imipenem/cilastatin/relebactam

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要